Cargando…

Nodal Basin Recurrence After Sentinel Lymph Node Biopsy for Melanoma: A Retrospective Multicenter Study in 2653 Patients

The objective of this study was to analyze different types of nodal basin recurrence after sentinel lymph node biopsy (SLNB) for melanoma. Patients and Methods: Kaplan–Meier estimates and the Cox proportional hazards model were used to study 2653 patients from 3 German melanoma centers retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Kretschmer, Lutz, Bertsch, Hans Peter, Zapf, Antonia, Mitteldorf, Christina, Satzger, Imke, Thoms, Kai-Martin, Völker, Bernward, Schön, Michael Peter, Gutzmer, Ralf, Starz, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616624/
https://www.ncbi.nlm.nih.gov/pubmed/26356697
http://dx.doi.org/10.1097/MD.0000000000001433
_version_ 1782396676407820288
author Kretschmer, Lutz
Bertsch, Hans Peter
Zapf, Antonia
Mitteldorf, Christina
Satzger, Imke
Thoms, Kai-Martin
Völker, Bernward
Schön, Michael Peter
Gutzmer, Ralf
Starz, Hans
author_facet Kretschmer, Lutz
Bertsch, Hans Peter
Zapf, Antonia
Mitteldorf, Christina
Satzger, Imke
Thoms, Kai-Martin
Völker, Bernward
Schön, Michael Peter
Gutzmer, Ralf
Starz, Hans
author_sort Kretschmer, Lutz
collection PubMed
description The objective of this study was to analyze different types of nodal basin recurrence after sentinel lymph node biopsy (SLNB) for melanoma. Patients and Methods: Kaplan–Meier estimates and the Cox proportional hazards model were used to study 2653 patients from 3 German melanoma centers retrospectively. The estimated 5-year negative predictive value of SLNB was 96.4%. The estimated false-negative (FN) rates after 1, 2, 3, 5, and 10 years were 2.5%, 4.6%, 6.4%, 8.7%, and 12.6%, respectively. Independent factors associated with false negativity were older age, fewer SLNs excised, and head or neck location of the primary tumor. Compared with SLN-positive patients, the FNs had a significantly lower survival. In SLN-positive patients undergoing completion lymphadenectomy (CLND), the 5-year nodal basin recurrence rate was 18.3%. The recurrence rates for axilla, groin, and neck were 17.2%, 15.5%, and 44.1%, respectively. Significant factors predicting local relapse after CLND were older age, head, or neck location of the primary tumor, ulceration, deeper penetration of the metastasis into the SLN, tumor-positive CLND, and >2 lymph node metastases. All kinds of nodal relapse were associated with a higher prevalence of in-transit metastases. The FN rate after SLNB steadily increases over the observation period and should, therefore, be estimated by the Kaplan–Meier method. False-negativity is associated with fewer SLNs excised. The beneficial effect of CLND on nodal basin disease control varies considerably across different risk groups. This should be kept in mind about SLN-positive patients when individual decisions on prophylactic CLND are taken.
format Online
Article
Text
id pubmed-4616624
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-46166242015-10-27 Nodal Basin Recurrence After Sentinel Lymph Node Biopsy for Melanoma: A Retrospective Multicenter Study in 2653 Patients Kretschmer, Lutz Bertsch, Hans Peter Zapf, Antonia Mitteldorf, Christina Satzger, Imke Thoms, Kai-Martin Völker, Bernward Schön, Michael Peter Gutzmer, Ralf Starz, Hans Medicine (Baltimore) 7100 The objective of this study was to analyze different types of nodal basin recurrence after sentinel lymph node biopsy (SLNB) for melanoma. Patients and Methods: Kaplan–Meier estimates and the Cox proportional hazards model were used to study 2653 patients from 3 German melanoma centers retrospectively. The estimated 5-year negative predictive value of SLNB was 96.4%. The estimated false-negative (FN) rates after 1, 2, 3, 5, and 10 years were 2.5%, 4.6%, 6.4%, 8.7%, and 12.6%, respectively. Independent factors associated with false negativity were older age, fewer SLNs excised, and head or neck location of the primary tumor. Compared with SLN-positive patients, the FNs had a significantly lower survival. In SLN-positive patients undergoing completion lymphadenectomy (CLND), the 5-year nodal basin recurrence rate was 18.3%. The recurrence rates for axilla, groin, and neck were 17.2%, 15.5%, and 44.1%, respectively. Significant factors predicting local relapse after CLND were older age, head, or neck location of the primary tumor, ulceration, deeper penetration of the metastasis into the SLN, tumor-positive CLND, and >2 lymph node metastases. All kinds of nodal relapse were associated with a higher prevalence of in-transit metastases. The FN rate after SLNB steadily increases over the observation period and should, therefore, be estimated by the Kaplan–Meier method. False-negativity is associated with fewer SLNs excised. The beneficial effect of CLND on nodal basin disease control varies considerably across different risk groups. This should be kept in mind about SLN-positive patients when individual decisions on prophylactic CLND are taken. Wolters Kluwer Health 2015-09-11 /pmc/articles/PMC4616624/ /pubmed/26356697 http://dx.doi.org/10.1097/MD.0000000000001433 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 7100
Kretschmer, Lutz
Bertsch, Hans Peter
Zapf, Antonia
Mitteldorf, Christina
Satzger, Imke
Thoms, Kai-Martin
Völker, Bernward
Schön, Michael Peter
Gutzmer, Ralf
Starz, Hans
Nodal Basin Recurrence After Sentinel Lymph Node Biopsy for Melanoma: A Retrospective Multicenter Study in 2653 Patients
title Nodal Basin Recurrence After Sentinel Lymph Node Biopsy for Melanoma: A Retrospective Multicenter Study in 2653 Patients
title_full Nodal Basin Recurrence After Sentinel Lymph Node Biopsy for Melanoma: A Retrospective Multicenter Study in 2653 Patients
title_fullStr Nodal Basin Recurrence After Sentinel Lymph Node Biopsy for Melanoma: A Retrospective Multicenter Study in 2653 Patients
title_full_unstemmed Nodal Basin Recurrence After Sentinel Lymph Node Biopsy for Melanoma: A Retrospective Multicenter Study in 2653 Patients
title_short Nodal Basin Recurrence After Sentinel Lymph Node Biopsy for Melanoma: A Retrospective Multicenter Study in 2653 Patients
title_sort nodal basin recurrence after sentinel lymph node biopsy for melanoma: a retrospective multicenter study in 2653 patients
topic 7100
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616624/
https://www.ncbi.nlm.nih.gov/pubmed/26356697
http://dx.doi.org/10.1097/MD.0000000000001433
work_keys_str_mv AT kretschmerlutz nodalbasinrecurrenceaftersentinellymphnodebiopsyformelanomaaretrospectivemulticenterstudyin2653patients
AT bertschhanspeter nodalbasinrecurrenceaftersentinellymphnodebiopsyformelanomaaretrospectivemulticenterstudyin2653patients
AT zapfantonia nodalbasinrecurrenceaftersentinellymphnodebiopsyformelanomaaretrospectivemulticenterstudyin2653patients
AT mitteldorfchristina nodalbasinrecurrenceaftersentinellymphnodebiopsyformelanomaaretrospectivemulticenterstudyin2653patients
AT satzgerimke nodalbasinrecurrenceaftersentinellymphnodebiopsyformelanomaaretrospectivemulticenterstudyin2653patients
AT thomskaimartin nodalbasinrecurrenceaftersentinellymphnodebiopsyformelanomaaretrospectivemulticenterstudyin2653patients
AT volkerbernward nodalbasinrecurrenceaftersentinellymphnodebiopsyformelanomaaretrospectivemulticenterstudyin2653patients
AT schonmichaelpeter nodalbasinrecurrenceaftersentinellymphnodebiopsyformelanomaaretrospectivemulticenterstudyin2653patients
AT gutzmerralf nodalbasinrecurrenceaftersentinellymphnodebiopsyformelanomaaretrospectivemulticenterstudyin2653patients
AT starzhans nodalbasinrecurrenceaftersentinellymphnodebiopsyformelanomaaretrospectivemulticenterstudyin2653patients